除了细胞减灭术联合腹腔热灌注化疗（CRS-HIPEC）外，全身化疗用于结直肠癌腹膜转移：关于对总生存期影响的关键系统评价
Systemic chemotherapy in addition to CRS-HIPEC for colorectal peritoneal metastases: A critical systematic review on the impact on overall survival.
作者信息
van den Heuvel Teun B M, Lurvink Robin J, Rovers Koen P B, van Hellemond Irene E G, de Hingh Ignace H J T
机构信息
Department of Surgery, Catharina Hospital Eindhoven, Eindhoven, The Netherlands.
Department of Oncology and Developmental Biology (GROW), Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
出版信息
J Surg Oncol. 2024 Nov;130(6):1378-1389. doi: 10.1002/jso.27849. Epub 2024 Sep 11.
In patients with resectable colorectal peritoneal metastases, it is unclear whether systemic chemotherapy, in addition to cytoreductive surgery-hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), improves overall survival (OS). This systematic review of 12 retrospective studies involving 3721 patients aimed to summarize the available evidence. Contradictory results were found regarding the effectiveness of neoadjuvant, adjuvant, and perioperative systemic therapies on OS, with a high risk of bias. Available evidence remains inconclusive, stressing the need for prospective, randomized trials, like the ongoing Dutch CAIRO6-trial.
在可切除的结直肠腹膜转移患者中，除了细胞减灭术-腹腔内热灌注化疗（CRS-HIPEC）外，全身化疗是否能改善总生存期（OS）尚不清楚。这项对12项涉及3721例患者的回顾性研究进行的系统评价旨在总结现有证据。关于新辅助、辅助和围手术期全身治疗对OS的有效性，发现了相互矛盾的结果，且存在高偏倚风险。现有证据仍然不明确，强调需要进行前瞻性随机试验，如正在进行的荷兰CAIRO6试验。
Zotero 插件